Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome

The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

Inclusion Criteria:

• Metabolic syndrome
• Fasting blood glucose between 100 mg/dL and 125 mg/dL
• Hypertension
• One additional criteria, Exclusion 1

Exclusion Criteria:

• Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus.
• Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa, hydralazine, or thiazide diuretic medication.